Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors

作者：Junzhe Huang, Changhui Lei, David H. Hsi, Minjuan Zheng, Hui Ma, Shengjun Ta, Rui Hu, Chao Han, Wenxia Li, Jing Li, Qu Dong, Fangqi Ruan, Jing Wang, Bo Wang, Xueli Zhao, Jiao Liu, Lina Zhao, Zhe Wang, Jian Yang, Liwen Liu · 发表于：JACC CardioOncology · 年份：2024 · DOI：10.1016/j.jaccao.2024.03.008 · 被引用次数：6 · 研究领域：Cardiac tumors and thrombi、Sarcoma Diagnosis and Treatment、Vascular Malformations and Hemangiomas

Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less-invasive palliative therapy option. This study aimed to evaluate the safety and efficacy of TARFACT. Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation. The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (P = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (P = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (P = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (P = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL ...